IJBPAS, August, 2022, 11(8): 3820-3825

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

# OVERVIEW OF THE ANALYTICAL METHOD OF BISOPROLOL IN BIOLOGICAL MATRICES

**PAVITHRA N[1], S.RAMACHANDRAN[1], P. SHANMUGASUNDARAM[2] AND M.VIJEY AANANDHI[1*]**

**1:** Department of Pharmaceutical Chemistry and Analysis, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai-600 117, Tamilnadu, India

**2:** Department of Chemistry, Thiruvalluvar Government Arts College, Rasipuram, Namakkal District. Tamilnadu, India

***Corresponding Author: Dr. M.Vijey Aanandhi: E Mail: ramachandrans.sps@velsuniv.ac.in**

**Received 16th Sept. 2021; Revised 20th Oct. 2021; Accepted 19th Dec. 2021; Available online 1st Aug. 2022**

https://doi.org/10.31032/IJBPAS/2021/11.8.6320

## ABSTRACT

**Bisoprolol** is a beta-blocker protocol was developed and validated for quantification of bisoprolol in human plasma. Bio-availability studies are analysed with the human plasma bind with bisoprolol. In assay methods are can be used to determine the presence of a specific proteinbinding are occur approximately 30% of serum within 2 to 4 hrs in renal function. The mass transition pairs of m/z 326 > 116 and 326.4 > 268.4 mass spectrometery method are determine the bisoprolol and internal examination. During method validation over the range of 0.4-100 ng/mL. Linearity, accuracy, precision, recovery, matrix effect, dilution test and stability are analysed. It is used to determine FTIR, HPTLC, LCMS, HPLC examine in the form of biological fluids. LCMS methods are more sensitive, specific and reproducible, suitable to determine the bisoprolol concentration.

**Keywords: Bisoprolol, FTIR, HPTLC, LCMS, HPLC**

## INTRODUCTION

Bisoprolol is a highly β1- selective adrenoceptor antagonist without stabilizing membrane and has a ISA characterization which means group of blockers that are able to stimulate adrenergic receptors (agonist effect) and to oppose the stimulating effect of catecholamines (antagonist effect) in a competitive way **[1]**. Almost 2% of Bisoprolol removed in faeces. Half life of bisoprolol is 10 to 12 hours, but patients with renal and liver impairment it will be prolonged **[1, 2]**.

Bisoprolol **(Figure 1)**, chemically is 1-{4-[(2-isopropoxyethoxy) methyl] phenoxy}-3-(isopropyl amino) propan-2-ol **[3]**. Bisoprolol fumarate is an antihypertensive drug used in the control of hypertension, stroke, and heart related problems. It is used to treat several cardiovascular diseases such as arrhythmia coronary heart disease, ischemic heart disease, and myocardial infarction. Pharmacokinetic activity of Bisoprolol when administered orally, absorption is complete while bioavailability reaches 90%. The Plasma peak levels arises in 2 to 4 hours. The therapeutic plasma range occurs in the range of 10 to 60 ng/mL concentration. The Protein binding of plasma is 30 to 35%. Polar metabolites are pharmacologically inactive when Bisoprolol is metabolized in liver. Approximately 50% in unchanged form and 50% as metabolites were excreted through the Kidneys.




**Figure 1: Structure of Bisoprolol**

One of the most powerful analytical tool is Liquid chromatography (LC) coupled with mass spectrometry (MS) detection for analysing of organic compounds **[4]**.

For determination of Bisoprolol in human plasma, serum and urine, several methods are used have been reported in the literature. These methods include`HPLC **[5-8]**, UV Spectrophotometric **[9]**, potentiometric method **[10]**, HPLC-UV, HPLC-FLD, HPLC-ED.

## MATERIALS AND METHODS

LC–MS/MS Equipment and Conditions maintain the liquid chromatography system (Shimadzu, Kyoto, Japan) was equipped with two LC-20AD pumps, a DGU-14AM vacuum degasser, a SIL-HTC autosampler and a controller module. The chromatographic separation was achieved on a Capcell Pak C18 MG column (100 × 2.0 mm, 5 μm, Shiseido, Japan) with a C18

guard column (4 × 3 mm, 5 µm, Phenomenex, USA) at room temperature. The mobile phase consisted of 0.1% formic acid in acetonitrile and water (22 : 78, v : v) at a flow rate of 0.3 mL/min. The samples were kept at 4°C in an autosampler and 5 µL was injected. Each run time was 4 min. Mass spectrometric detection was performed on an API 3000 triple quadrupole instrument (ABI-SCIEX, Toronto, Canada) using multiple reaction monitoring (MRM). A turbo spray interface with positive ionization mode was used. The precursor-to-product ion transitions m/z 326.3 → 116.3 for Bis and 331.3 → 121.3 for IS were monitored. The mass spectrometer was operated with unit resolution for both Q1 and Q3 detection. The data were acquired and processed using Analyst 1.4 software package.

**Sample Preparation**

All frozen human plasma samples were maintained at required temperature. To a 1.5 mL polypropylene test tube, 50 µL plasma test and 100 µL acetonitrile containing 4 ng/mL IS were added, and the blend was vortexed completely for 10 s. Following centrifugation at 18,000 rpm for 3 min, 50 µL of supernatant was weakened with 50 µL water, and 5 µL of the example was infused into the LC-MS/MS framework.

**Standard, Quality Control and IS Preparation**

Stock solution of bisoprolol (both 0.1 mg/mL) were ready in methanol. Working standard arrangements of bisoprolol were weakened with 20% methanol. All standard procedure were put away at 4°C when not being used. Alignment norms (0.5, 1, 5, 10, 25, 50 and 100 ng/mL) were ready by spiking the functioning standard arrangements of Bis into human plasma.

Quality control (QC) stock arrangement of Bisoprolol (0.1 mg/mL) was ready from a different gauging and was additionally disintegrated in 20% methanol presented. Weakenings were utilized to get ready four degrees of QCs in human plasma: high QC (80 ng/mL), medium QC (40 ng/mL), low QC (1.5 ng/mL) and lower QC (0.5 ng/mL). The QC principles were ready in plasma same as the alignment guidelines. QCs were put away at −20°C. The IS working arrangement was ready by weakening its stock solution with acetonitrile to 4 ng/mL and put away at 4°C **[11]**.

**Method Validation**

The method was validated by verifying linearity, lower limit of quantification (LLOQ), intra- and inter-assay precision and accuracy, matrix effect and recovery and stability.

The spectrophotometric method for the quantitative determination of bisoprolol involved the formation of bisoprolol fumarate by the formation of complex with methyl orange produced at different pH values. The limit of detection (LoD) was 0.19 µg/mL and the limit of quantification (LoQ) was 0.64 µg/mL **[12]**.

LCMS the samples of human plasma are undergoes alkalization with NaoH extract with the TMBE after evaporation evaporation and reconstitute with 0.25%ml of 0.1% formic acid acetonitrile.No more causes in physically and chemically of samples. So LCMS method are applicable for examining the bioavailability and pharmacokinetics of bisoprolol **[13-15]**.

**DISCUSSION**

HPLC-MS/MS technique was produced for the assurance of 5-ISMN in human plasma. It was realized that steady isotope-marked mixtures had comparable construction and physicochemical properties to target analytes to decrease framework impacts.To accomplish the quantitative assurance of Bisoprolol in plasma, the electrospray ionization interface boundaries were upgraded for most extreme plenitude of the sub-atomic particles of the mixtures. Obtaining boundaries were dictated by direct mixture of 1 µg/mL arrangement of Bis and IS into the mass spectrometer at a stream pace of 10 µL/min. Variable mass spectrometric conditions (source temperature, particle shower voltage, crash energy, and so on) had recently been upgraded. Obviously the analysis of bisoprolol is suitable method for spectroscopy is LCMS is determine the drug elimination rate, concentration of drug are present activity of renal and non- renal functions.

**CONCLUSION**

All analytical methods has been determination of bisoprolol fumarate in the matters of raw materials, pharmaceutical preparations and biological fluids. the analysis method for the mixture of bisoprolol fumarate with other substances has been developed. Spectrophotometric analysis methods are carry out quickly but LCMS are better than vaoltammetry method are more accuracy, linearity, precision, reliability. LC-MS are complicated but more sensitive.

**ACKNOLEDGEMENT**

The authors are immensely thankful to the organization Vels Institute of Science, Technology and Advanced Studies (VISTAS) for providing helpful support for the study.

**REFERENCES**

**[1]** Ioan Tilea., Daniela Popa., Daniela lucia Muntean., Andreeaelena Bocicor., Laurian Vlase and Brindusa Tilea., Determination of Bisoprolol in Human Plasma by Lc-ms/ms for Therapeutic Drug Monitoring, ClinCardiol., 2014; 20: 2236-2245.

**[2]** Jane K. McGavinand Gillian M. Keating., Bisoprolol A Review of its use in chronic heart failure., *McGavin & Keating* Drugs 2002; 62: 18

**[3]** Hemavathi G and Hipparagi S.M., Sensitive Liquid Chromatography Tandem Mass Spectrometric Method for the simultaneous Determination of Bisoprolol and Triamterene in Human plasma., 2017; 10:4.

**[4]** Gabriela Peste., Nela Bibire., Mihai Apostu., Aurel Vlase and Corneliu Oniscu., A New Liquid Chromatography- Tandem Mass Spectrometry Method for Determination of Bisoprolol in Human Plasma Samples., 2009; 736327: 8.

**[5]** Liliyalogoyda., Sergiy Kovalenk., MoustafaGaafar., Ahmed M. Abdel Megied and Fawzy A. Elbarbry., A Validated LC–MS/MS method for the quantification of amlodipine, bisoprolol, enalapril and enalaprilat—Application to pharmacokinetic study in healthy volunteers, *Microchemical Journal, 2020*; 104700: 155.

**[6]** Tomasz Tuzimski and Anna Petruczynik., Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM)
**2020**, *25*(17), 4026

**[7]** Sevgi Tatar Ulu and Zeynep Aydoğmuş., An HPLC Method for the Determination of Bisoprolol in Human Plasma and its Application to a Pharmacokinetic Study,
*Journal of Chromatographic Science*, August 2012; 50(7): 615–619.

**[8]** Kishwar Saleem., Imran Ali., Umma Kulsum and Hassan Y. Aboul-Enein., Recent developments in HPLC Analysis of b-Blockers in Biological samples, Journal of Chromatographic Science 2013; 51: 807–818.

**[9]** Sevgi Tatar Ulu and Zeynep Aydog mus., An HPLC Method for the Determination of Bisoprolol in Human Plasma and its Application to a Pharmacokinetic Study, Journal of Chromatographic Science, 2012; 50: 615–619.

**[10]** Shahinaz A. Mohammed., Mohammed E. Adam and Shaza W. Shantie., Development and Validation of UV Spectrophotometric Method for Determination of Bisoprolol Fumarate in Bulk and Pharmaceutical Dosage Forms, Mediterranean Journal of Chemistry, 2017; 6(5): 196-195.

**[11]** Gang Yi Liu., Wei Wang., Jing Ying Jia., Chuan Lu., Yan Meiliu., Meng Qi Zhang., Shuijun Li and Chen Yu., Liquid chromatography Tandem Mass spectrometry method for Determination of Bisoprolol in Human plasma using D5 Bisoprolol as the internal standard, *Biomed. Chromatogr.* 2010; 24: 574–580

**[12]** Gabriela Peste., Aurel Vlase and Corneliu Oniscu., Experimental research for Determination of bisoprololfumarate in human plasma samples using Liquid chromatography - tandem mass spectrometry (LC-MS/MS) technique, Romanian Biotechnological Letters, *Romanian Biotechnological Letters*, 2010; 15: 2.

**[13]** KhaledElgendy, Mohamed A.F. Elmosallamy, Moustafa K. Soltan, Alaa S. Amin and Dina S. Elshaprawy., Novel potentiometric methods for the estimation of bisoprolol and alverine in pharmaceutical forms and human serum., Reviews in Analytical Chemistry 2021; 40: 127–135.

**[14]** Shubhada Pawar., Ashpak Tamboli and Snehal Patil., UV Spectrophotometric area under curve method for the simultaneous Determination of Bisoprololfumarate and Cilnidipine in Pharmaceutical dosage form, World Journal of Pharmaceutical Research., 2020; 9: 5.

**[15]** Almesya, Melinida overview of the analutical methods of bisoprolol fumarate in pharmaceutical preparations and biological matrix from 2000-2020 December 2020. World Journal of Pharmaceutical Research., 2020; 9: 12.